SCHEMBL19435489

SCHEMBL19435489

COc1ccc2cnsc2c1Br

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
XPO1 O14980 1/20 0.37
IDO1 P14902 4/20 0.36
TDO2 P48775 4/20 0.36
ALDH1A1 P00352 4/20 0.36
CHUK O15111 1/20 0.35
PRKD3 O94806 1/20 0.35
PRKCG P05129 1/20 0.35
PRKCB P05771 1/20 0.35
PRKCA P17252 1/20 0.35
CSNK2A2 P19784 1/20 0.35
PRKCH P24723 1/20 0.35
PRKCI P41743 1/20 0.35
CSNK2B P67870 1/20 0.35
CSNK2A1 P68400 1/20 0.35
PRKCE Q02156 1/20 0.35
PRKCQ Q04759 1/20 0.35
PRKCZ Q05513 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL911727 0.76 MCHR1 (0.42) XPO1ALDH1A1NQO2KDM4EHPGD
SCHEMBL19435555 0.72 PDGFRB (0.39) ALDH1A1KDM4EHPGDMAPK1HSD17B10
SCHEMBL19435560 0.72 PDGFRB (0.39) ALDH1A1KDM4EHPGDMAPTMEN1
SCHEMBL659303 0.72
SCHEMBL659713 0.72 SLC22A12 (0.31)
SCHEMBL4801476 0.71 NQO2 (0.38) IDO1TDO2ALDH1A1CHUKPRKD3
SCHEMBL19435492 0.71 SLC22A12 (0.51) ALDH1A1KDM4EHPGDMAPK1MAPT
SCHEMBL19435467 0.69 NPC1 (0.47) CYP19A1CYP11B1CYP11B2KDM4EMAPK1
SCHEMBL19435541 0.69 SLC22A12 (0.39)
SCHEMBL5419829 0.69 ALDH1A1 (0.41) ALDH1A1NQO2KDM4EHPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3241822-B1 URAT1 INHIBITOR NIPPON CHEMIPHAR CO (JP) 2021-03-24 EP disclosed
CN-107108478-B URAT1 inhibitors 日本化学药品株式会社 2020-04-24 CN disclosed
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 US disclosed
EP-3241822-A1 URAT1 INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2017-11-08 EP disclosed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170290795-A1 URAT1 INHIBITOR SLC10A1, XDH, URB2 CYP19A1 2285/4885CYP11B1 785/4885CYP11B2 1365/4885
US-10173990-B2 URAT1 inhibitor SLC10A1, XDH, URB2 CYP19A1 2222/4885CYP11B1 766/4885CYP11B2 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.